Table 2.
Survival outcomes of key studies evaluating the right therapy for localized gastric adenocarcinoma.
| Trial | Arms | n | Outcome |
|---|---|---|---|
| SWOG 9008/INT-011631 | Surgery vs. surgery → CRT | 275 vs. 281 | 3-year OS rate, 41% vs. 50%; HR, 1.35; 95% CI: 1.09–1.66; P=0.005 |
| ARTIST42 | Surgery (D2) → CT vs. surgery (D2) → CRT | 228 vs. 230 | 5-year OS rate, 73% vs. 75%; HR, 1.130; 95% CI: 0.775–1.647; P = 0.5272 |
| ACTS GC43, 44 | Surgery (D2) vs. surgery (D2) → S1 | 530 vs. 529 | 3-year OS rate, 70.1% vs. 80.1%; HR, 0.68; 95% CI: 0.52–0.87; P = 0.003 |
| CLASSIC45 | Surgery (D2) vs. surgery (D2) → XELOX | 520 vs. 515 | 5-year OS rate, 69% vs. 78%; HR, 0.66; 95% CI: 0.51–0.85; P = 0.0015 |
| MAGIC47 | Surgery vs. ECF×3 → surgery → ECF×3 | 253 vs. 250 | 5-year OS rate, 23.0% vs. 36.3%; HR, 0.75; 95% CI: 0.60–0.93; P = 0.009 |
| FLOT4-AIO48 | FLOT×4 → surgery → FLOT×4 vs. ECF×3 → surgery → ECF×3 | 356 vs. 360 | 5-year OS rate, 45% vs. 36%; HR, 0.77; 95% CI: 0.63–0.94; P=0.012 |
| ST0349 | (ECX + bevacizumab)×3 → surgery → (ECX + bevacizumab)×3 vs. ECX×3 → surgery → ECX×3 | 533 vs. 530 | 3-year OS rate, 48.1% vs. 50.3%; HR, 1.09; 95% CI: 0.91–1.29; P = 0.36 |
SWOG 9008/INT-0116: Southwest Oncology Group 9008/Intergroup trial 0116; CRT: chemoradiation therapy; OS: overall survival; HR: hazard ratio; CI: confidence interval; ARTIST: Adjuvant Chemoradiation Therapy in Stomach Cancer; CT: chemotherapy; ACTS GC: Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer; CLASSIC: Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer; XELOX: capecitabine/oxaliplatin; MAGIC: Medical Research Council Adjuvant Gastric Infusional Chemotherapy; ECF: epirubicin, cisplatin, and 5-fluorouracil; FLOT4-AIO: perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma; FLOT: 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel; ECX: epirubicin, cisplatin, and capecitabine; ST03: Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer.